BGC vs CME: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: BGC is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BGC and CME share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BGC and CME exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

BGC Group (NASDAQ: BGC) is a global marketplace, data and financial-technology company built around an interdealer brokerage that sits between the large banks and trading firms, executing and processing trades across fixed income, foreign exchange, energy, commodities, shipping and equities. Historically its economics were driven by human (voice) brokers who earn commissions on transaction volume, so revenue rises when markets are volatile and active and falls when they are quiet. Over the past several years management has pushed hard to shift the mix toward higher-margin electronic and data products under the Fenics brand, and, most notably, to launch the FMX Futures Exchange, a US interest-rate futures and treasuries venue backed as equity owners by a roster of major banks and market makers including Goldman Sachs, J.P. Morgan, Citi, Morgan Stanley and Citadel Securities.

Full BGC guide

CME Group operates the largest futures and options marketplace in the world, spanning six asset classes: interest rates, equity indexes, energy, agricultural commodities, metals and foreign exchange. It earns money mainly from clearing and transaction fees charged on every contract traded and cleared, plus market-data and information-services revenue, and it benefits from owning both the exchange and the clearinghouse that guarantees trades. Volumes rise with hedging demand and market volatility, which is why record average daily volume has been the main engine of recent results.

Full CME guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BGC drivers: FMX Futures Exchange optionality; Electronic and data mix shift (Fenics).
• CME drivers: Record trading volumes; Interest-rate and volatility franchise.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: FMX is unproven and faces CME Group's entrenched liquidity, network effects and incumbency in rate futures, so it could burn cash without ever reaching critical mass. For CME, revenue is cyclical and tied to trading volumes, so a prolonged low-volatility environment can depress activity and fees.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BGC if you believe its drivers more; CME if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BGC and CME guides.

BGC. As of July 2026 BGC trades around $11 to $12 per share for roughly a $5.3 billion market cap. The forward P/E near 8x on adjusted earnings looks low versus exchange peers, but the trailing GAAP P/E is much higher because GAAP earnings run well below the adjusted numbers. Much of the valuation debate hinges on whether FMX and Fenics justify an exchange-like multiple over time.

CME. CME posted record FY2025 revenue of about $6.5 billion and net income near $4.1 billion, then opened 2026 with record Q1 revenue of roughly $1.88 billion, up 14 percent, and adjusted EPS of $3.36. The shares trade around $240 for a market cap near $87 billion, a trailing P/E of roughly 21, with a high blended dividend yield reflecting the regular-plus-variable payout structure.

Headline figures (approximate, July 2026): BGC shows revenue (ttm) ~$2.8B, q1 2026 revenue ~$955M (up ~44% YoY), q1 2026 adjusted ebitda ~$253M, market cap ~$5.3B; CME shows revenue (ttm) ~$6.7B, fy2025 revenue ~$6.5B, net income (ttm) ~$4.2B, market cap ~$87B.

BGC and CME are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BGC and CME exposure against your real portfolio. It is not an investment adviser.